Performance funds/ETFs
Growth in fund currency
Available documents (NL)
Available documents (EN)
Available documents for this product 
Quote
Quote
€27,72
Quote date
31-03-2026
Performance in EUR
Date
31-03-2026
This year
-0,72%
1 week
4,45%
1 month
-2,33%
3 months
-0,72%
6 months
28,45%
1 year
59,59%
3 years (annualised)
22,28%
5 years (annualised)
-
Since start (annualised)
20,32%
Indicators
Standard deviation (3yr)
24,00%
Share ratio (3yr)
0,96
Beta (3yr)
-
Alpha (3yr)
-
Tracking error (3yr)
-
Top 10 holdings (31-12-2025)
Praxis Precision Medicines Inc Ordinary Shares
6,60 %
Revolution Medicines Inc Ordinary Shares
4,55 %
argenx SE ADR
4,06 %
BridgeBio Pharma Inc
4,01 %
Vertex Pharmaceuticals Inc
3,84 %
Regeneron Pharmaceuticals Inc
3,51 %
AstraZeneca PLC ADR
3,50 %
United Therapeutics Corp
3,15 %
Gilead Sciences Inc
3,10 %
Ascendis Pharma AS ADR
3,10 %
Fees
Entry fee
-->Tarievenkaart / Cost information sheet
Exit charges
-->Tarievenkaart / Cost information sheet
Estimated ongoing charges
1,23%
Dividend
Dividend paying
No
Characteristic
Asset Manager
Janus Henderson
Asset class
Equities
Investment category
Equities - Healthcare
Active/Passive
Active
Fund code
212809
Fund code fractional orders
-
Fund manager name
Daniel Lyons|Agustin Mohedas|Andy Acker
ISIN
LU2441283277
Sustainable Classification
Art. 8, ESG integration
Sustainability Rating
Domicile
Luxembourg
Currency
EUR
Fund size (mio)
1.340,48 (31-03-2026)
Cut-off time
-
Execution date
-
Inception date
25-02-2022
Benchmark
NASDAQ Biotechnology TR
Minimum investment amount
-
Assortiment
Self Directed Investing Plus, Investment advice